Latest Conference Articles

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain

Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.

Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.

Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.

Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.

Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.

Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.

Xiuning Le, MD, PhD, discusses treatment selection among targeted therapies for HER2-mutant NSCLC.

David Gerber, MD, discusses the evolution of ALK TKIs and the central nervous system toxicity tradeoffs seen with later-generation agents in NSCLC.

New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.

Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.

Jay M. Lee, MD, discusses the role of ctDNA in guiding surveillance and treatment escalation decisions in resected NSCLC.

Amy L. Cummings, MD, discusses patient selection for adjuvant immunotherapy in resectable non–small cell lung cancer.

Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.

Sandip Patel, MD, discusses key unmet needs and open questions surrounding EGFR-mutant NSCLC that has transformed to SCLC.

Alissa Cooper, MD, discusses evolving strategies for biomarker-driven patient selection with tarlatamab in small cell lung cancer.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX in pancreatic adenocarcinoma.

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.

Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress

In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.

Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.

First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.

Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.

Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.

At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.

Elisrasib produced a 58.8% ORR and 12.2-month median PFS in KRAS G12C inhibitor–naive NSCLC and remained active in G12C inhibitor–refractory disease.